Patent ID: 8431342

Claim:
A method of determining survival prognosis in a subject with acute myeloid leukemia (AML), comprising: obtaining a test sample from subject having, or suspected of having AML, wherein the sample is extracted from at least one of: blood, bone marrow, and tissue suspected of having leukemic cells, measuring, by hybridization assay, the level of at least one gene product of miR-182 in the test sample, comparing the level of miR-182 gene product in the test sample relative to a control level of miR-182 gene product in at least one control sample, and determining the subject's survival prognosis, wherein, if the level of the miR-182 gene product in the test sample is high relative to the level of a corresponding miR-182 gene product in the control sample, the subject is determined to have a shorter overall survival prognosis.